S&P Companies not as negative; Gene Therapy manufacturing is stretched thin

Update: 2018-11-05

Description

Happy national doughnut day! Fewer companies in the S&P are providing negative guidance. What does this mean? How CFOs are protecting their balance sheets in the event their manufacturing is disrupted.

Comments

In Channel

Where does the market go from here? Will retail investors sell?

2018-11-2109:21

What’s the deal with GE?

2018-11-1608:34

We changed our name and Amazon announced their new locations!

2018-11-1410:31

A $500 Million Biotech IPO. Amarin Data

2018-11-1209:04

Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision.

2018-11-0909:14

Why cost should only be one consideration

2018-11-0605:24

S&P Companies not as negative; Gene Therapy manufacturing is stretched thin

2018-11-0507:21

Lessons from Halloween when your kids have peanut allergies

2018-11-0108:56

Swimming and the Dow Jones

2018-10-2905:09

President’s Drug Pricing Speech and New CA Sexual Harassment Law

2018-10-2508:49

M&A Activity - Will Market Forces Play a Role?

2018-10-2403:28

Episode 36 - Concept or Concrete?

2018-10-1902:09

Episode 35 - McDermott Will & Emery Dealmaking Symposium Recap

2018-10-1809:57

Episode 34 - DeviceTalks Recap

2018-10-1707:39

Episode 33 - Chinese Espionage and Cyber Coverage

2018-10-0406:17

Episode 32 - Can the Biotech IPO Market Sustain Itself?

2018-10-0305:35

I’m Doing an IPO and My D&O Insurance is Expensive

2018-10-0108:03

FDA Condemns Undamaged Product - Insurance Should Have Paid

2018-09-2505:16

Episode 29 - MD Bio-Tech Conference Recap

2018-09-2111:28

Episode 28 - NJTC CFO Forum Recap

2018-09-1910:20

00:00

S&P Companies not as negative; Gene Therapy manufacturing is stretched thin

Life Sciences Rush Hour - Inve

#box-pro-ellipsis-176159456086376{-webkit-line-clamp:2;}S&P Companies not as negative; Gene Therapy manufacturing is stretched thin

S&P Companies not as negative; Gene Therapy manufacturing is stretched thin

Life Sciences Rush Hour - Inve

S&P Companies not as negative; Gene Therapy manufacturing is stretched thin